The central goal of this NOFO is to establish robust proof of concept in mouse models or cell-based models of AD/ADRD that will enable rational drug repositioning and the development of precision combination therapies for the treatment and prevention of AD/ADRD.
Amount: $7,550,000
Due Date: 06/09/2025; 10/06/2025